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Abstract: Estrogen receptors promote target gene transcription when they form a dimer, in
which two identical (homodimer) or different (heterodimer) proteins are bound to each other.
In hormone-dependent cancers, hormone receptor dimerization plays pivotal roles, not only in
the pathogenesis or development of the tumors, but also in the development of therapeutic
resistance. Protein–protein interactions (PPIs), including dimerization and complex formation,
have been also well-known to be required for proteins to exert their functions. The methods
which could detect PPIs are genetic engineering (i.e., resonance energy transfer) and/or antibody
technology (i.e., co-immunoprecipitation) using cultured cells. In addition, visualization of the target
proteins in tissues can be performed using antigen–antibody reactions, as in immunohistochemistry.
Furthermore, development of microscopic techniques (i.e., electron microscopy and confocal laser
microscopy) has made it possible to visualize intracellular and/or intranuclear organelles. We have
recently reported the visualization of estrogen receptor dimers in breast cancer tissues by using the
in situ proximity ligation assay (PLA). PLA was developed along the lines of antibody technology
development, and this assay has made it possible to visualize PPIs in archival tissue specimens.
Localization of PPI in organelles has also become possible using super-resolution microscopes
exceeding the resolution limit of conventional microscopes. Therefore, in this review, we summarize
the methodologies used for studying PPIs in both cells and tissues, and review the recently reported
studies on PPIs of hormones.
Keywords: protein–protein interaction; co-immunoprecipitation; bioluminescence resonance energy
transfer/förster resonance energy transfer; immunohistochemistry; in situ proximity ligation assay;
super-resolution microscopy; estrogen receptor
1. Introduction
The quaternary structure of proteins, such as their dimerization, is achieved via specific and
non-specific non-covalent interactions. Non-specific interactions occur due to hydrophobic effects or
van der Waals forces, and specific interactions occur due to electrostatic forces. It is well known that
hydrophobicity is the main driving force behind protein folding [1]. Electrostatic interactions are also
known to play pivotal roles in protein folding, stability, flexibility, and function [1]. Protein–protein
interaction (PPI) has also been demonstrated to be important in determining protein function.
For instance, epidermal growth factor receptor (EGFR) binds adaptor proteins, such as growth factor
receptor binding protein 2 (Grb2), via an intracellular phosphorylation site in order to activate the
downstream signaling cascade [2,3]. In addition to growth signaling, Grb2 is required for endocytosis
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of EGFR, which is mediated by clathrin [4]. Prior to the activation of intracellular signaling, EGFR
binds to its ligands and undergoes homodimerization or heterodimerization with another EGFR family
receptor, such as the human epidermal growth factor receptor (HER) 2, HER3, and HER4 [5].
In the nuclear receptor super family, dimerization (homodimerization or heterodimerization) is a
crucial process for the activation of nuclear receptors after ligand binding. Activated nuclear receptors
then recruit cofactors forming a receptor–cofactor complex. Among all the nuclear receptor super families,
the estrogen receptor (ER) is most well studied because it plays an important role in hormone-related
growth in hormone-dependent cancers, especially breast and endometrial cancers [6,7]. ER has several
functional domains which include the ligand binding domain (LBD), DNA binding domain (DBD), hinge
region, and two activation function domains (AF-1 and AF-2) [8–10]. Ligands such as estradiol induce ER
dimerization and its subsequent binding to estrogen response elements located in the promoter regions
of ER-target genes, upregulating their transcription [11]. Two isoforms of ER, ERα (NR3A1) and ERβ
(NR3A2) have been well characterized so far. In addition, it is well known that ERβ has five splicing
variants, ERβ1-5 (ERβ2 is also known as ERβcx) [12,13]. ERα (66 kD) is also reported to have several
splicing variants, two of which are ERα-36 (kD) and ERα-46 (kD) [14,15]. Binding of the ligands to the
ER usually leads to ER dimerization, forming ERα homodimers, ERβ homodimers, and ERα/ERβ
heterodimers in the nucleus [16,17]. Although the pattern of formation of heterodimers with ER
variants remains unclear, it is suggested that the heterodimers may regulate a different set of genes
than the homodimers. Recruitment of the dimer, along with co-regulators, known as nuclear receptor
co-repressors (NCORs) and nuclear receptor co-activators (NCOAs), is required to exert transcriptional
activity of ER dimers on target genes [18]. The PPIs between ER and its coregulators can be predicted
using the in silico Search Tool for Retrieval of Interacting Genes and proteins (STRING) [19] (Figure 1).
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protein 1; JUN, Jun proto-oncogene; SRC, V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog (avian); NCOA, Nuclear receptor coactivator; NCOR1, Nuclear receptor corepressor 1. (B) 
ESR2 protein (ERβ) interaction on confidence prediction. MAPK11, Mitogen-activated protein kinase 
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Figure 1. Prediction using the STRING database (https:/ string-db.org/). (A) ESR1 protein (ERα)
interaction on confidence prediction. AKT1, V-akt murine thymoma viral oncogene homolog 1; CCND1,
Cyclin D1; IGF1R, Insulin-like growth factor 1 receptor; NRIP1, Nuclear receptor interacting protein 1;
JUN, Jun proto-oncogene; SRC, V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian);
NCOA, Nuclear receptor coactivator; NCOR1, Nuclear receptor corepressor 1. (B) ESR2 protein (ERβ)
interaction on confidence prediction. MAPK11, Mitogen-activated protein kinase 11; NR0B1, Nuclear
receptor subfamily 0, group B, member 1; DDX54, DEAD (Asp-Glu-Ala-Asp) box p lyp ptide 54; FOS,
FBJ murine osteosarcoma viral oncogene homolog; NOS3, Nitric oxide synthase 3 (endothelial cell);
NCOA, Nuclear receptor coactivator; MED1, Mediator complex subunit 1; NR0B2, Nuclear receptor
subfamily 0, group B, member 2.
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Tamoxifen, which is a selective ER modulator and has an inhibitory effect on estrogen-dependent
transcription in breast cancer, inhibits recruitment of NCOA1-3 and induces recruitment of NCOR1
and NCOR2 [18,20–22].
Results of those described above indicated that evaluation of intracellular PPIs could offer
significant advantages for understanding hormonal signaling in hormone-dependent cancers.
Many methodologies have been proposed for the evaluation of PPI [23]. PPI analysis by in vivo
imaging using xenograft or transgenic mice is possible [23,24]. Although gene recombination and
antibody engineering technologies are employed for investigation of PPI, it is mostly examined using
in vitro cell culture models. In addition, using appropriate technologies for PPI analysis, the dynamics
of intracellular PPIs in living cells could be visualized at in vitro levels [25–27]. Novel technologies of
in vitro PPI examination have been introduced [28–30]. On the contrary, detection of intracellular PPI
by histological and pathological analyses using tissue samples is considered difficult, as compared to
in vitro analysis using cultured cells.
2. Co-Immunoprecipitation
Co-immunoprecipitation (Co-IP) has been classically used for detection of PPI in vitro.
Co-IP includes using an antigen–antibody complex as a bait and the target interacting protein as
prey. Typically, cell lysate is reacted with the bait-specific antibody. Along with the bait protein and
any bait-associated proteins, the prey protein (the interaction partner) will be co-precipitated. The bait
protein interacts with its specific antibody, which is bound to micro-beads, such as agarose, sepharose,
or magnetic beads [31]. Under the presence of the prey protein that binds to bait protein in the sample,
a bait–prey complex will be formed and it will be co-precipitated. Subsequently, the prey protein can be
detected by downstream analysis, such as the western blot. If the prey protein is unknown, advanced
proteomic analysis such as mass spectrometric analysis can be employed for its identification [32].
Co-IP does not prove that the two target proteins are directly bound to each other, because the presence
of a third protein cannot be ruled out.
In hormone-dependent cancer research, it is well known that ERα is co-immunoprecipitated
with NCOR in MCF-7 cells treated with tamoxifen, but not in untreated or estradiol-treated cells [21].
Mohammed H et al. [33] reported the presence of estrogen-enriched ER interactive proteins by using
a novel technique called rapid immunoprecipitation mass spectrometry of endogenous proteins
(RIME). Among 108 ER-associated proteins extracted, GREB1 was the most significantly increased
as an estrogen-ER-interactive protein [33]. GREB1 is demonstrated to have an essential role in
ER-mediated transcription. The principle of the co-IP itself does not vary; however, downstream
analysis of the new target proteins affecting hormone signal are being constantly developed in
hormone-dependent cancers.
3. Bioluminescence Resonance Energy Transfer and Förster Resonance Energy Transfer
Resonance energy transfer (RET) technologies such as bioluminescence RET (BRET) and Förster
(or Fluorescence) RET (FRET) is also used widely to examine PPI in vitro [34,35]. FRET uses the
principle that an acceptor molecule (fluorophore) absorbs energy emitted from an excited donor
molecule (fluorophore). Detection of FRET is usually done by irradiating the donor using its excitation
wavelength and measuring the fluorescence intensity of the donor or acceptor [36,37]. Cyan variant of
GFP (CFP) and yellow version of GFP (YFP) are usually employed as donor and acceptor molecules,
respectively [37,38]. During detection of the donor’s fluorescence intensity, if the donor and acceptor
are near, the energy derived from the donor is absorbed by the acceptor, thus the fluorescence intensity
of the donor decreases. When both molecules are relatively separated, the fluorescence intensity of the
donor increases. When measuring the fluorescence intensity corresponding to the acceptor, the results
are reversed. Likewise, the principle of BRET is based on energy transfer between fusion proteins
containing Renilla luciferase (RLuc) from Renilla reniformis as a donor molecule, and fluorophores
such as GFP and YEP as acceptor molecules [39,40]. Since bioluminescence technology is used in
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BRET, it has an advantage over FRET because it does not require an excitation light source and its
corresponding system for the donor [34]. Therefore, BRET is applicable to various PPI examinations
including mouse in vivo imaging [23,24,41,42]. BRET can be used for studying deep tissues of mouse
as it uses a highly sensitive cooled charge coupled device (CCD) camera or complementary metal
oxide semiconductor (CMOS)-based optical imaging instrument for detection [42–44].
ER dimerization was reported using both FRET [17] and BRET [45]. Michelini et al. [45] established
a monitoring system for estrogen-like compounds using BRET of ERα homodimerization as an index of
ERα activation. ERα proteins fused with Rluc (donor) and enhanced YFP (acceptor) were used for BRET
in their study [45]. Techniques such as BRET have been used for PPI analysis. The AlphaScreen assay
from PerkinElmer (Waltham, MA, USA) uses as a photosensitizer (phthalocyanine), which converts
ambient oxygen (O2) present in the donor beads to singlet oxygen (1O2) through excitation [46].
When acceptor beads are near the donor, i.e., the distance is less than 200 nm, energy is transferred
from 1O2 to the thioxene in the acceptor, and radiation (520 to 620 nm) is emitted from the acceptor.
Interaction of ER and retinoic acid receptor with their co-activator was screened using the AlphaScreen
assay [47]. These findings suggest that RET technologies, including AlphaScreen, are useful methods
for screening possible hormone–receptor interactions and interactions with coregulators.
4. Protein Detection Methods
Several protein detection methods are available for in vitro, ex vivo, and in vivo analysis. In 1960,
radio immunoassay (RIA) was established for measurement of insulin in plasma by Yalow, a Nobel
Prize laureate [48]. Enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA) are
non-radioisotope methods developed and used traditionally to quantitatively detect target proteins or
antibodies in various type of samples such as serum, plasma, cell lysate, and tissue homogenate [49–51].
Western blotting, which includes gel electrophoresis of the protein, followed by electrophoretic transfer
to a membrane, is also a well-established method [52,53]. Western blotting has the advantage that it can
be used to determine the molecular weight of target proteins, while RIA, EIA, and ELISA can be used
for quantification of the molecules. In addition to the analysis described above, multiplex analyses are
also becoming a popular technique for the detection of target proteins and their interaction partners.
Antibody array enables detection of many target proteins, including cytokines and phosphorylated
proteins [54,55]. Flow cytometric analysis could also be used to detect protein expression in cells
using antigen–antibody reactions. Furthermore, the technique of simultaneously detecting multiple
cytokines by combining bead-based labeling technology and flow cytometry (multiplex cytokine
assay) has been frequently used [56]. However, the protein detection methods described above cannot
distinguish the intracellular or intratissue localization of target proteins.
Immunohistochemistry is a classical microscopy-based technique for visualizing the target protein
in tissues and cells using a specific antibody. Immunohistochemistry was invented in 1941 by
Coons and co-investigators [57] and is a principal technique for pathological diagnosis. For example,
in hormone-dependent cancers, ER, progesterone receptor (PgR), HER2 and Ki67 are routinely
examined by immunohistochemistry (Figure 2) for planning therapeutic strategies for breast cancer
patients. According to evaluation based on these biomarkers, breast cancer is divided into four
subtypes namely, luminal A, luminal B, HER2 type, and triple-negative type mostly based upon
results of immunohistochemistry above. Using the companion diagnostic assay, which detects a
predictive biomarker, patients with cancer were classified as responders and non-responders to
its target therapy. HER2 test using immunohistochemistry, which is named “HercepTest (Dako,
Carpinteria, CA, USA) [58]”, is considered as the prototypic companion diagnostic employed in
immunohistochemistry [59].
Immunohistochemistry is currently widely used at the global level. It is possible to identify the
localization of a target protein in normal tissues and disease in routinely processed tissue specimens
by immunohistochemistry. Steroid hormone receptors can also be detected by immunohistochemistry
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in several hormone-dependent cancers (Figure 3). Immunocytochemistry can be used for examining
the subcellular localization of proteins in single cells.
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Figure 2. Immunohistochemistry of biomarker proteins used for pathological diagnosis of breast cancer
subtypes. Immunostaining for ERα (A); progesterone receptor (B); and HER2 (C) was performed using
autostainer, Ventana Benchmark ULUTRA staining system (Roche). Immunoreactivities of ERα and
progesterone receptor were detected in the nucleus of breast carcinoma cells. HER2 was detected in cell
membranes of breast carcinoma cells. Top photographs are of a lower magnification (scale bar, 200 µm),
and bottom photographs are of a higher magnification (scale bar, 50 µm).
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In addition, protein localization at the organelle level can be detected using transmission
and immunoelectron microscopes (Figure 4). In immunoelectron microscopic analysis, secondary
antibodies labeled with gold or silver colloids are allowed to interact with primary antibodies
and target protein complex. Immunoelectron microscopy is traditionally known to be effective in
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detecting microbial pathogens [60]. In addition, in renal diseases such as monoclonal gammopathy,
immunoelectron microscopic analysis provides useful information for diagnosis [61,62]. In cultured
cell as well as tissue diagnosis, immunoelectron microscopic analysis provides significant intracellular
information, which cannot be obtained using a light microscope [63].
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Figure 4. Immunoelectron microscopy. (A) Expression of chemoki e rece tor ( XCR, arrow heads) on
the membrane of lymphocytes aggregated in colitis. Left photograph is at low magnification, and right
is at high magnification (scale bar, 1 µm). Gold colloid conjugated antibody for CXCR, and the signal
was amplified by the silver nanoparticles. Asterisks indicate nuclei of lymphocytes; (B) Secretion of
5-hydroxytryptamine (arrow heads) from gastric cancer cells. Colloidal Gold Conjugated secondary
antibody was employed (scale bar, 0.5 µm). The asterisk indicates nucleus of gastric carcinoma cell.
Kocanova et al. [64] demonstrated that the intranuclear accumulation pattern of ERα in SK19
varied depending on estradiol, SERM and ER-inhibitor (ICI182,780) by using confocal laser scanning
microscopy. In addition, the ac lation pattern of ERα observed by confocal microscopy was
also c fi in MCF-7 cells by immunoelectron microscopic analysis [64]. ERα molecules labeled
with ld particles w re detected within 100 n from each other in estradiol or ICI182,780 treated
MCF-7 cells [64]. This study also made it possible to visualize the intranuclear localization of ERα
and 20S proteasome subunit α2 (α2) in SK12 cells by double-immunonanogold labeling approach [64].
ERα was labeled with 10 nm gold particles and α2 was labeled with 6 nm gold particles, respectively.
In estradiol treated MCF-7 cells, interaction of ERα and α2 in the nuclear microdomains of about
100 nm in diameter was observed [64].
5. Proximity Ligation Assay
Advanced tech iques based on immunohistochemistry have been developed, nd in situ
proximity ligat on assay (PLA) was developed o vi ualize PPI of two proteins in tissue samples [65,66].
This method has been us d to detect PPIs and post-translational modifi ations (PTMs) by n bling
target proteins to interact with specific antibodies, which ligate with special oligonucleotides, which are
subsequently amplified. The principle of in situ PLA is summarized in Figures 5 and 6. Dual targets of
primary antibodies (e.g., one that recognizes ERα and another that recognizes ERβ) were employed to
detect PPI. During in situ detection of PTM, two specific antibodies, such as antibodies against EGFR
and the phosphorylated form of EGFR, are selected for in situ PLA. The PLA kit (Duolink PLA) sold
by Olink Bioscience (Uppsala, Sweden), and now available from Sigma-Aldrich/Merck (Darmstadt,
Germany) was used.
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Figure 6. PLA system: procedure. (A) When t e istance between two targets is more tha 40 nm,
PLUS oligo and MINUS oligo, which is linked to primary or secondary anti o ies, cannot hybridize
with each other; (B) When these probes ar pre ent at less than 40 nm, they hy ridize and then ligate
to form a circle; (C) The DNA circle undergo s several hundredfold replication b the rolling-circle
amplification (RCA) reaction; (D) The fluorescently labeled oligonucleotides will hybridize to the RCA
product. In this Scheme, as an example, heterodimer of ERα and ERβ induced by estrogen-binding
(pink) are depicted.
We recently demonstrated that ER dimerization was induced by estrogen treatment in breast
cancer cell lines (Figure 7). ERα homodimers in MCF7 cells treated with estradiol for 15, 45, and 90
min were detect d in the nucleus compared to ir local zation in t e control c lls [63]. In this study,
we employed a oring system for the PLA sig al, which is quantified as the area of PLA-fluorescence
dots in the nucleus using a image analyzer (Lumina Vision, Mitani Corp., Fuk i, Japan). The PLA
score of ERα hom dimer was obta ned e tradiol reatment after 15 o 45 min in MCF-7 cells. These
findings did indicate that the interaction of estroge with ER could be vis alized by the detection of
ERα ho odimer by using in situ PLA. We also detected both ERα homodimer (Figure 8) and ERα/β
heterodimer by PLA in breast carcinoma tissues, which were 10% formalin-fixed paraffin-embedded
(FFPE) for pathological diagnosis [67]. It was impossible to detect ER activation in breast carcinoma
tissues, although PLA technology might be able to resolve this issue in the future.
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paraffin-embedde (FFPE) samples were used for t l gical diagnosis. ERα antibodies, SP-1 and
6F11 were employed. Both cases with low- (A) and high-PLA score (B) were demonstrated. PLA signals
(red dots) were detected in the nucleus of breast carcinoma cells. Nuclei were stained blue (DAPI).
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photographs are of a higher magnification. Scale bar, 20 µm.
In addition, we also reported the visualization of heterodimers of ERβ variants in breast
carcinoma cell line [63,68]. In a previous s udy, the PLA core of ERα/β1 heterodimers increased
after 15 min of stimulation with estradiol, ho gh ther w s no increase in the PLA score of ERα/β2
or ERα/β5 heterodimers in MCF-7 cells stimulated by estradiol. It is reported that ERβ2 could
form heterodimers with ERα or ERβ1 in a ligand independent manner [69,70]. Ligand independent
dimerization of ERβ5 remains unknown, but the binding affinity of ERβ5 for estradiol is known
to be lesser than that of ERβ1 [71]. In general, the isoforms of ERβ prevent ERα-dependent
transcriptional activities, thus preventing the formation of the heterodimer (ERα/β). However,
these inhibitory effects are thought to vary according to the isoforms [72]. In situ PLA analysis
using normal and cancerous human tissues may clarify the significance of the heterodimer patterns
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observed in each ERβ and ERα isoform. Flanders et al. [73] demonstrated the presence of the Smad
complex (Smad2/3-Smad1/5/9) in breast cancer tissues using tissue microarray and brightfield PLA.
In brightfield PLA, horseradish peroxidase (HRP)-conjugated oligonucleotides were employed instead
of fluorescence labeled oligonucleotides [74]. Intratumoral binding of estradiol and ER in breast cancer
tissues was visualized by PLA using specific antibodies [74]. In the presence of specific antibodies,
the hormone receptor-binding assay using tissues by PLA could be possible.
Interaction of androgen receptor with JunD in prostate cancer LNCaP cells was identified by
PLA, and this interaction was inhibited by a selected lead chemical [75]. We recently reported the
interaction of HER2 with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)
in breast cancer tissues [76]. We further confirmed that the PLA score of HER2/CEACAM6 was
significantly associated with efficacy of HER2 inhibition after treatment with trastuzumab in breast
cancer patients [76]. With respect to the PLA of HER2, a heterodimer with HER3 has been reported,
and its effect in the inhibition of the HER2 homodimer formation has been investigated [77–80]. It was
reported that Pan-HER and EGFR-targeting monoclonal antibody inhibited binding of EGFR to its
receptor and disrupted EGFR-dimerization levels which were evaluated by PLA [81]. Moreover,
DNA damage-induced protein complexes in acute lymphoblastic leukemia cell lines were examined
using PLA [82]. The reports described above suggest the possibility of PLA as a diagnostic tool for
prediction of efficacy and resistance towards target therapies in several types of cancer, including
hormone-dependent cancers. Quantification of the amplified connector oligos by quantitative PCR,
and quantification of fluorescence signals obtained through flow cytometry have been studied using
PLA [82–84] thus it can be used as a diagnostic tool [85].
6. Super-Resolution Microscopy
Optical microscopy has contributed immensely to the elucidation of the microstructure of cells,
but the resolution of an optical microscope is limited because of its diffraction limit, explained
by the Abbe’s law [86,87]. Intranuclear distributions of ER and AR have been examined with a
confocal laser scanning microscope (LSCM) [88–91]. An intranuclear formation of both ER and AR
dimers has been well known to change after their treatment with ligands. LSCM has been conducted
to observe the intracellular localization of target proteins as it has a resolution of about 200 nm,
which is recognized as the optical diffraction limit [86]. The Nobel Prize in Chemistry in 2014 was
awarded for the discovery of super-resolved fluorescence microscopy, where resolution beyond the
diffraction limit was achieved. Recently, several types of super-resolved fluorescence microscopes
have been developed which have a high resolution, such as structured illumination microscopy
(SIM), stimulated emission depletion (STED) microscopy, photoactivated localization microscopy
(PALM), fluorescence photoactivation localization microscopy (fPALM), (direct) and the stochastic
optical reconstruction microscopy (STORM/dSTORM) [81,82,87]. The resolutions of each of these
super-resolution microscopes are as follows: SIM, 100 nm; STED, 30–70 nm; PALM/fPALM, 10–55
nm, and STROM/dSTROM, 10–55 nm [92]. Among these super-resolution microscopes, SIM is
considered the most accessible. In Figure 9, immunofluorescence of ERα recognized by two different
monoclonal antibodies in MCF-7 was captured by Nikon’s SIM (N-SIM, Nikon, Tokyo, Japan) with
a lateral resolution of approximately 100 nm [68]. In this case, the secondary antibodies against the
two primary antibodies are labeled in fluorescence red and green, respectively. Therefore, when the
two antigens are near, i.e., within 100 nm, yellow fluorescence is observed. In MCF-7, red, green, and
yellow fluorescence was detected in the nucleus. Red and green indicate ERα monomers, yellow is
considered to include ERα homodimer. In our previous research, the intratumoral yellow area in
MCF-7 significantly increased after treatment with estradiol [68]. A similar result was obtained by
PLA analysis. Although SIM cannot be used to visualize a larger region, it has the advantage that
the change in the number and distribution of the intraorganelle target signals, including those of the
nucleus, can be evaluated.
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Figure 9. SIM analysis. In this case, ERα homodimer was detected. ERα antibodies, rabbit monoclonal
SP-1 and mouse monoclonal 6F11 were employed. (A) Secondary antibodies were labeled with Alexa
Fluor 594 (Red) and Alexa Fluor 488 (Green), respectively. (B) In conventional fluorescence microscopy
(Left), the fluorescence signal from the entire molecule in the sample is simultaneously detected,
and the fluorescence from each molecule overlaps. In SIM analysis, fluorescence from only a small
part of the fluorescent molecule is detected, making it possible to determine the exact position of the
molecule [93]. (C) When the two molecules are located at 100 nm or more, they can be recognized as
red and green fluorescence, respectively. When two molecules are close to each other (<100 nm), they
can be visualized with marginal yellow fluorescenc . (D) Intranuclear localization of ERα in MCF-7
was observed by N-structured illumination microscopy (SIM). Scale bar, 5 µm.
Gonad trophic ormones such as follicle-sti l i hormone (FSH) and lutei izing h rmone
(LH) derived from the pituitary gland, bind to their corresponding receptors in ovarian granulosa
(FSH-R) and theca (LH-R) cells, respectively. Jones and co-investigators [94] demonstrated the existing
patterns of LH-R, which were monomers, dimers, and various oligomers, in HEK293 transfected
Tag-labeled LH-R using photoactivatable dye (PD)-PALM [94]. Dimerization pattern of LH-R and
FSH-R was also revealed using PD-PALM in HEK293 transfected Tag-linked LH-R and FSH-R [95].
LH-R is demonstrated to interact with FSH-R in the form of distinct heterooligomers as well as simple
heterodimers [95]. In br ast cancer cell lines, cluster formation, including formation of homo and
heterodimers of HER family (HERs) memb rs, such as HER2 and HER3, was examined by pectral
precisi n distance/position determination microscopy (SPDM) [96,97]. HERs cluster form tion and the
distance between the clusters were different in normal epithelia and cancerous cell lines; furthermore,
they changed after treatment with the HER3 ligands and were sensitive to the HER2 inhibitor [96,97].
Therefore, visualization of the intracellular microenvironment by super-resolution microscopy is useful
for elucidating the steroid function and predicting the drug efficacy based on the receptor dimer
formation pattern.
In our previous study, immunoreactivity of CEACAM6 in breast carcinoma tissues was not
associated with the efficacy of HER2 inhibitor, trastuzumab, in the breast cancer patients examin d [76].
How ver, interac f CEACAM6/HER2 vis alized by in situ PLA was significantly associated
with the efficacy of trastuzuma tr atment [76]. Therefore, detection of PPI could better enable
evaluation of intracellular signal transduction in cancer cells in pathological specimens. The assumed
maximum distance between antigen recognition sites of target proteins is <40 nm (10–30 nm [98]) using
probe-linked primary antibodies, and increases if probe-linked secondary antibodies are used [98].
Furthermore, PPI is well known to be complex, with mediator proteins required to detect the interaction
between the two target proteins. The issue with regard to the detection limit of “distance” is important,
as in any other method, and it will be difficult to prove whether the two proteins are directly or
indirectly coupled with each other. Two or more PPI analysis methods are required to confirm an
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analysis [98]; thus, it may be useful to refer to a simulation or prediction analysis software, which
is available online [19,99]. Antibody technology is extensively utilized in PPI detection methods,
therefore confirmation of the specificity of the antibody to the antigen should be done carefully
and reliably.
7. Future Perspectives on Exploring PPI in Hormone-Dependent Cancers
Inhibitors that directly target estrogen receptor/co-activator binding (co-activator binding
inhibitors: CBI) have been developed [100–102]. Both ERα and ERβ bind co-factor proteins
through LxxLL motifs. It is reported that tetrahydro-iso-alpha acid inhibits the estrogen-stimulated
transcriptional activity of ERs by interfering with the binding of ERs to LxxLL motifs in breast cancer
cell line MCF-7 [102,103]. One of the enzothiophenone derivatives also has an inhibitory action
on the binding of ERα to LxxLL, and the compound also represses the transcription of the mutant
form of ERα gene (ESR1) [104]. Hormone- or endocrine-therapy has been applied to patients with
ERα-positive breast cancer, and it has been noted that ESR1 mutation is involved in endocrine therapy
resistance [105]. Therefore, CBI is considered beneficial for endocrine therapy resistant cases too.
Since scanning tunneling microscopy and atomic force microscopy (AFM) were developed in the
1980s, a wide variety of scanning probe microscopy (SPM) techniques have been developed based
on their principles [106]. The principle of SPM is that a sharp-tipped probe closely scans the surface
of the sample and an image is obtained by scanning the probe, while keeping the physical quantity
exchanged between the probe and the sample constant [106,107]. Understanding biomaterials at the
nanoscale has advanced by the development of STM technology. It is possible to detect ER dimers
using SPM, and SPM is considered as a usefull tool for assessing compouds which have the ability to
either active or inhibit ER dimerization [108–110]. Since estrothiazine, like natural estrogens, shows
ER dimerization [108–110] as evaluated by AFM analysis, it is considered as an ER agonist [109,110].
In recent years, PPI has been considered one of the important concepts in drug discovery, and PPI
itself is regarded as a drug target. PPI is a key mechanism in understanding steroid hormone signals,
and is an indispensable part of hormone-dependent cancer research. Furthermore, evaluation of PPI is
thought to provide useful information, not only as a diagnostic tool for disease, but also as a predictive
marker for the efficacy of the molecular-targeted agents.
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